Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352339 | 0.91 | GGPS1 (0.41) | TRPM8GGPS1FDPS | |
| SCHEMBL2347905 | 0.84 | TSHR (0.35) | TSHRSMN1; SMN2FDPS | |
| SCHEMBL4538909 | 0.80 | TSHR (0.30) | TSHR | |
| SCHEMBL2346979 | 0.79 | GGPS1 (0.31) | GGPS1FDPS | |
| SCHEMBL2348714 | 0.77 | GGPS1 (0.39) | GGPS1FDPS | |
| SCHEMBL2344972 | 0.74 | TSHR (0.38) | TSHRSMN1; SMN2GGPS1FDPS | |
| SCHEMBL2349335 | 0.74 | TSHR (0.33) | TSHRSMN1; SMN2TRPM8GGPS1FDPS | |
| SCHEMBL2347116 | 0.74 | FDPS (0.36) | TSHRSMN1; SMN2FDPS | |
| SCHEMBL2349482 | 0.73 | FDPS (0.38) | TSHRSMN1; SMN2GGPS1FDPS | |
| SCHEMBL5664044 | 0.71 | TSHR (0.30) | TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078724-B1 | PROCESS FOR PRODUCTION OF DIALKYLTIN DIALKOXIDES | ASAHI CHEMICAL IND (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2226328-B1 | PROCESS FOR PRODUCTION OF ALKYL TIN ALKOXIDE COMPOUND, AND PROCESS FOR PRODUCTION OF CARBONATE ESTER USING THE COMPOUND | ASAHI KASEI CHEMICALS CORP (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-8168812-B2 | Process for producing alkyl tin alkoxide compound and process for producing carbonic acid ester using said compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8008518-B2 | Process for producing dialkyl tin dialkoxides | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20100292496-A1 | Process for Production of Alkyl Tin Alkoxide Compound, and Process for Production of Carbonic Acid Ester Using the Compound | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2226328-A1 | PROCESS FOR PRODUCTION OF ALKYL TIN ALKOXIDE COMPOUND, AND PROCESS FOR PRODUCTION OF CARBONATE ESTER USING THE COMPOUND | Asahi Kasei Chemicals Corporation (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-20100041908-A1 | PROCESS FOR PRODUCING DIALKYL TIN DIALKOXIDES | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2078724-A1 | PROCESS FOR PRODUCTION OF DIALKYLTIN DIALKOXIDES | Asahi Kasei Chemicals Corporation (JP) | 2009-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041908-A1 | PROCESS FOR PRODUCING DIALKYL TIN DIALKOXIDES | DEK, DDT, DERA | TSHR 2537/4885SMN1; SMN2 4349/4885TRPM8 4020/4885 |
| US-20100292496-A1 | Process for Production of Alkyl Tin Alkoxide Compound, and Process for Production of Carbonic Acid Ester Using the Compound | OXSR1, AOC2, OXER1 | TSHR 249/4885SMN1; SMN2 2341/4885TRPM8 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.